Search
Clinician Ordering Portal
In this case, a more accurate assessment of the state of disease was attained through 40-GEP testing. Traditional staging methods, including AJCC8 and BWH, overestimated our patient’s risk profile. More research needs to be completed surrounding gene testing and metastatic risk. Our goal with this case is to contribute to the growing body of literature surrounding the use of gene expression profile testing in cutaneous cancer.
Scientific evidence
The tissue systems pathology test objectively risk-stratifies patients with Barrett’s esophagus: a multicenter US clinical experience study
Oct 2023
TissueCypher risk-stratifies BE patients ≥ 65 years old independently of clinicopathologic variables and has significantly higher sensitivity for detection of progressors than pathology diagnosis of LGD.
Publication: Poster presentation (S600) at ACG 2023, Vancouver
40-gene expression profile representative of metastatic risk of squamous cell carcinoma in a Mohs surgical patient
Oct 2023
Publication: Cureus
Gene expression differences identified in skin samples of early-stage mycosis fungoides, atopic dermatitis, and psoriasis
Oct 2023
Publication: Poster, presented at the 2023 Fall Clinical Dermatology Conference®, Las Vegas, Nevada, October 19-22, 2023
The integrated i31-GEP test outperforms the MSKCC nomogram at predicting SLN status in melanoma patients
Sep 2023
This study evaluates the performance of DecisionDx-Melanoma and the MSKCC nomogram in a head-to-head study in 465 patients withT1 or T2 tumors and known SLN status
Publication: Anticancer Research
A Tissue Systems Pathology Test Enables Risk-Aligned Management of Patients with Non-Dysplastic Barrett’s Esophagus: Case Reports from a Gastrointestinal Surgery Center
Sep 2023
TissueCypher demonstrated clinical utility in NDBE patients by guiding risk-aligned upstaging of care and potential improved health outcomes in BE patients.
Publication: Poster presentation (61) at AFS 2023, Dallas
The importance of incorporating drug-drug interactions and lifestyle factors in pharmacogenomics-guided medication management for patients with major depressive disorder in a randomized controlled trial
Sep 2023
In this study, drug-drug interactions accounted for 32% of all IDgenetix-guided drug recommendations, and lifestyle factors accounted for 11%. Incorporating these non-genetic factors in IDgenetix testing significantly impacts the number of drug recommendations and improves remission rates in patients with moderate to severe depression.
Publication: Poster at Psych Congress 2023
The tissue systems pathology-9 test provides clinically-impactful risk stratification in patients with Barrett’s esophagus: clinical experience in a multicenter cohort
Aug 2023
This study evaluated the use of the validated, commercially-available tissue systems pathology test (TissueCypher, TSP-9) to risk-stratify BE patients in a large clinical practice cohort.
Publication: Diseases of the Esophagus
31-gene xxpression profile testing in cutaneous melanoma and survival outcomes in a population-based analysis: A SEER collaboration
Jun 2023
Study data from Castle Biosciences' collaboration with the National Cancer Institutes SEER program registries.
Publication: JCO-PO
Multi-colored lesion with uncertain malignant potential
Jun 2023
Conflicting clinical and histopathological findings are resolved with the use of GEP test results.
Atypical melanocytic proliferation on sensitive preauricular check
Jun 2023
Histopathological assessment of a melanocytic lesion on the check could not definitively rule out melanoma leading to the use of GEP prior to determining surgical management.
Abnormally pigmented lesion with uncertain malignant potential
Jun 2023
With benign GEP results, dermatopathologist adjusts diagnosis to a benign neoplasm and patient avoids re-excision.
Irregular papule with atypical histopathological findings and borderline/uncertain diagnosis
Jun 2023
Definitive diagnosis cannot be reached in an irregular, raised papule on the dorsal foot.